Efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: a systematic review and meta-analysis.

Jiawen Deng,Daniel Rayner,Harikrishnaa B Ramaraju,Umaima Abbas,Cristian Garcia,Kiyan Heybati,Fangwen Zhou,Emma Huang,Ye-Jean Park,Myron Moskalyk

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases（2023）

引用 12|浏览6

暂无评分

摘要

Fluvoxamine remains a candidate pharmacotherapy for treating COVID-19 in outpatients. Medium-dose fluvoxamine may be preferable over low-dose fluvoxamine.

查看译文

关键词

COVID-19,Fluvoxamine,Meta-analysis,SARS-CoV-2,Selective serotonin reuptake inhibitor

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要